These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1209 related articles for article (PubMed ID: 30810350)

  • 1. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA
    Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
    JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
    Suresh V; Mills JA; Croarkin PE; Strawn JR
    Depress Anxiety; 2020 Sep; 37(9):926-934. PubMed ID: 32579280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
    Jakubovski E; Varigonda AL; Freemantle N; Taylor MJ; Bloch MH
    Am J Psychiatry; 2016 Feb; 173(2):174-83. PubMed ID: 26552940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
    Mansoor B; Rengasamy M; Hilton R; Porta G; He J; Spirito A; Emslie GJ; Mayes TL; Clarke G; Wagner KD; Shamseddeen W; Birmaher B; Ryan N; Brent D
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):458-67. PubMed ID: 24024532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
    Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
    Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
    Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
    Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
    Landén M; Högberg P; Thase ME
    J Clin Psychiatry; 2005 Jan; 66(1):100-6. PubMed ID: 15669895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
    Moore ML; Eichner SF; Jones JR
    Ann Pharmacother; 2004 Sep; 38(9):1515-9. PubMed ID: 15292500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
    Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
    Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
    Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.